Financials
Financial year 2025
MEDIGREX from Wuustwezel, company number BE0465660871, closed financial year 2025 with a result of € 198,059 after tax. For that financial year MEDIGREX recorded a gross margin of € 603,444 and equity of € 535,052. Compared with financial year 2024, the result moved from € 218,115 to € 198,059. The company is profitable. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on April 27, 2026.
€ 535,052
▲ 59% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 198,059
▼ 9% vs 2024
Profit after tax over the fiscal year.
€ 414,934
▲ 25% vs 2024
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2025. Retained profit grew to € 473,052.
People and assets in 2025
4.8
▲ 0.2 vs 2024
Average over the fiscal year, from the social balance sheet.
€ 299,457
▲ 21% vs 2024
€ 62,400 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 44,055
▼ 24% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 142,107
▲ 48% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 42,710
▼ 25% vs 2024
Taxes, VAT and social contributions still to pay.
| 2021 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 325,020 | € 489,550 | € 586,978 | € 603,444 | ▲ 3% |
| Profit after taxes | € 66,255 | € 163,681 | € 218,115 | € 198,059 | ▼ 9% |
| Equity | € 924,955 | € 618,878 | € 336,993 | € 535,052 | ▲ 59% |
| Total debts | € 199,409 | € 297,924 | € 808,958 | € 648,014 | ▼ 20% |
| Cash | € 178,597 | € 240,662 | € 331,448 | € 414,934 | ▲ 25% |
| Land & buildings | € 200,746 | € 169,091 | € 153,633 | € 145,494 | ▼ 5% |
| Retained profit | € 862,955 | € 556,878 | € 274,993 | € 473,052 | ▲ 72% |
| Dividend | € 25,000 | € 50,000 | € 500,000 | € 0 | ▼ 100% |
| Balance sheet total | € 1,124,364 | € 916,802 | € 1,145,952 | € 1,183,066 | ▲ 3% |
| Employees (FTE) | 3.6 | 4.4 | 4.6 | 4.8 | ▲ 0.2 |
Key figures of MEDIGREX, fiscal years 2021 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 30 April 2027.
What happened to MEDIGREX?
What happened at MEDIGREX in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 198,059 (▼ 9% vs 2024). Source: NBB ↗
- Kempen Pharma BV became a director. NBB
- New establishment in Wuustwezel. KBO
- Start of the company according to the CBE. KBO
In short
From € 66,255 profit in 2021 to € 198,059 profit in 2025.
Paid € 225,633 in corporate taxes since 2021.
Best year ever: 2024, with € 218,115 profit.
On average € 125,700 of value added per employee in 2025.
Management
The stake of KEMPEN PHARMA comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.
MEDIGREXBehind MEDIGREX is Kempen Pharma BV. The shares are held by KEMPEN PHARMA (100%).
Directors
According to the 2025 annual accounts
since 2013
Shareholders
100%
Participations
No participations in other companies reported.
Establishments
Establishment units
Physical locations of this company
Bredabaan (Centrum) 403
2990 Wuustwezel
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0465.660.871
- VAT number
- BE 0465.660.871
- Registered office
- Bredabaan (Centrum) 403, 2990 Wuustwezel
- Names & denominations
- MEDIGREX
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 25 March 1999
- Peppol
- Active · Active since 27 Nov 2025
- Activities · NACE
Apothekers
Detailhandel in farmaceutische producten